Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults

BACKGROUND: Merozoite surface protein 1(42) (MSP1(42)) is a leading blood stage malaria vaccine candidate. In order to induce immune responses that cover the major antigenic polymorphisms, FVO and 3D7 recombinant proteins of MSP1(42) were mixed (MSP1(42)-C1). To improve the level of antibody respons...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ellis, Ruth D., Martin, Laura B., Shaffer, Donna, Long, Carole A., Miura, Kazutoyo, Fay, Michael P., Narum, David L., Zhu, Daming, Mullen, Gregory E. D., Mahanty, Siddhartha, Miller, Louis H., Durbin, Anna P.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2010
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2809736/
https://ncbi.nlm.nih.gov/pubmed/20107498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0008787
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars